iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
July 08, 2024 07:00 ET
|
iTeos Therapeutics Inc.
WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and...
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
May 10, 2024 08:26 ET
|
iTeos Therapeutics Inc.
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor...
iTeos Therapeutics Announces $120 Million Registered Direct Offering
May 10, 2024 08:24 ET
|
iTeos Therapeutics Inc.
- Led by existing investors RA Capital Management and Boxer Capital- Purchase price of $17.50 represents a premium of approximately 44% to last close- Further strengthens balance sheet with pro forma...
iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
April 27, 2020 01:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020 – Initial data from the dose escalation portion of the Phase 1/2a trial in 21...
iTeos Therapeutics to Present Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
April 20, 2020 07:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020 Gosselies, Belgium and Cambridge, MA – April 20,...
iTeos Therapeutics to Present at Cowen 40th Annual Health Care Conference
February 24, 2020 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at Cowen 40th Annual Health Care Conference Cambridge, MA and Gosselies, Belgium – February 24, 2020 – iTeos Therapeutics SA, a privately-held biotechnology company...
iTeos Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
November 26, 2019 07:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference Cambridge, MA and Gosselies, Belgium – November 26, 2019 – iTeos Therapeutics SA, a privately-held biotechnology...
iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer
August 13, 2019 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer Gosselies, Belgium and Cambridge, MA – 13 August, 2019 – iTeos Therapeutics SA, a privately-held biotechnology...
iTeos Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference
August 07, 2019 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference Gosselies, Belgium and Cambridge, MA – August 7, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company...
iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019
March 29, 2019 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019 Gosselies, Belgium and...